AIA Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.86M | Buy |
30,232
+3,741
| +14% | +$1.22M | 0.21% | 60 |
|
|
2025
Q1 | $7.15M | Buy |
26,491
+3,643
| +16% | +$984K | 0.18% | 68 |
|
|
2024
Q4 | $5.38M | Sell |
22,848
-5,369
| -19% | -$1.26M | 0.13% | 77 |
|
|
2024
Q3 | $7.76M | Buy |
28,217
+8,789
| +45% | +$2.42M | 0.2% | 58 |
|
|
2024
Q2 | $4.72M | Buy |
19,428
+4,784
| +33% | +$1.16M | 0.14% | 81 |
|
|
2024
Q1 | $2.19M | Hold |
14,644
| – | – | 0.07% | 129 |
|
|
2023
Q4 | $2.8M | Hold |
14,644
| – | – | 0.12% | 87 |
|
|
2023
Q3 | $2.59M | Buy |
14,644
+2,050
| +16% | +$363K | 0.13% | 85 |
|
|
2023
Q2 | $2.39M | Buy |
12,594
+6,910
| +122% | +$1.31M | 0.12% | 86 |
|
|
2023
Q1 | $1.14M | Buy |
5,684
+685
| +14% | +$137K | 0.06% | 139 |
|
|
2022
Q4 | $1.19M | Buy |
4,999
+1,075
| +27% | +$255K | 0.07% | 117 |
|
|
2022
Q3 | $785K | Buy |
3,924
+1,039
| +36% | +$208K | 0.05% | 151 |
|
|
2022
Q2 | $421K | Buy |
+2,885
| New | +$421K | 0.02% | 257 |
|